drugset / Trial / NCT06799559
Study on the Efficacy and Safety of QLM1016 in Schizophrenia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The study will evaluate the antipsychotic efficacy of QLM1016 in a multicenter, randomized, double-blind, parallel controlled study in patients diagnosed with schizophrenia.
Timeline
- Start
- 2025-05
- Primary completion
- 2026-07
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aripiprazole | Other / unclassified | 10 mg | Oral |
| Comparator | Aripiprazole | Other / unclassified | 20 mg | Oral |
| Subject | QLM1016 | Unknown | 3 mg | Oral |
| Subject | QLM1016 | Unknown | 6 mg | Oral |